49 results about "Cycloalternan" patented technology

A process produces unsubstituted or at least singly substituted cycloalkanones by electrochemical oxidation of unsubstituted or at least singly substituted, saturated cycloaliphatic hydrocarbons in the presence of an inorganic or organic nitrate salt in an electrolysis cell in a reaction medium in the presence of oxygen.

The invention relates to a solvent composition comprising at least one specific cycloalkanone-based solvent as a first solvent and at least one specific amide as a second solvent. The invention also relates to the use of the solvent composition for producing agrochemical formulations and to the agrochemical formulations themselves.

The present invention relates to a method for producing unsubstituted or at least monosubstituted α,ω-dicarboxylic acids or ketocarboxylic acids and unsubstituted or at least monosubstituted cycloalkanones by electrochemically oxidizing unsubstituted or at least monosubstituted mono- or polyunsaturated cycloalkenes and unsubstituted or at least monosubstituted saturated alicyclic hydrocarbons in an electrolytic cell in the presence of inorganic or organic nitrates in a reaction medium in the presence of oxygen.

Compositions containing tri-cyclopentadiene and processes for making same. In some embodiments, the composition can include 1 wt % to 6 wt % of TCPD-7; 5 wt % to 25 wt % of TCPD-3; 15 wt % to 30 wt % of TCPD-5; and 55 wt % to 75 wt % of TCPD-1, where all wt % values are based on the combined weight of TCPD-7, TCPD-3, TCPD-5, and TCPD-1 in the composition. In some embodiments, the composition can further include di-cyclopentadiene. In other embodiments, the composition can further include di-cyclopentadiene, tetra-cyclopentadiene, and optionally one or more oligomers heavier than tetra-cyclopentadiene. In some embodiments, the composition can be made via a continuous process.

A process produces unsubstituted or at least singly substituted cycloalkanones by electrochemical oxidation of unsubstituted or at least singly substituted, saturated cycloaliphatic hydrocarbons in the presence of an inorganic or organic nitrate salt in an electrolysis cell in a reaction medium in the presence of oxygen.

Disclosed in the present invention are a PARP1 / CDK6 dual-target inhibitor, and a preparation method therefor and the use thereof. The PARP1 / CDK6 dual-target inhibitor is a compound having a structure represented by formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from or , and R is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, sulfhydryl, cyano, nitro, methoxy, a C1-C8 alkyl, or a C3-C8 cycloalkyl. The PARP1 / CDK6 dual-target inhibitor of the present invention exhibits good effects against human breast cancer cells, and maintains a good in vitro enzyme inhibitory activity against CDK6 and PARP1. Disclosed in the present invention is the use of a CDK6 / BRD4 dual-target inhibitor in the preparation of a drug for treating PARP1 / CDK6-mediated diseases. Disclosed in the present invention is the use of a PARP1 / CDK6 dual-target inhibitor in the preparation of a drug for treating or preventing triple-negative breast cancer.

The invention discloses a 1, 2-dihydrobenzo silacyclohexane compound and a preparation method and application thereof, and discloses a preparation method for synthesizing two silicon-containing six-membered ring compounds with different substituent positions in one step by starting from the same raw material and controlling reaction conditions. A complex formed by a metal catalyst palladium salt and a phosphine ligand is used as a catalyst precursor, the chemical selectivity of a product is controlled by changing the structure of the ligand, and a series of silicon-containing six-membered ring compounds with high yield and high chemical selectivity are efficiently synthesized through intermolecular cycloaddition reaction. Compared with traditional cycloaddition and other reactions, the method for synthesizing the naphthenic compound is more efficient, direct and effective, various silicon heterocyclic compounds with different substituent groups, which cannot be prepared by a traditional method, can be obtained, and the method is widely applied to the fields of material chemistry and pharmaceutical chemistry.

The application relates to the technical field of chemical synthesis, and particularly discloses a method for constructing cycloalkanol by nickel-catalyzed asymmetric hydrogenation of tri-substituted enone, and a chiral alcohol prepared by the method. The method uses alpha, beta-unsaturated ketone with different molecular structures as a substrate to construct chiral alcohol with double chiral centers, hydrogen is added to reduce the enyl group first, and then hydrogen is added to reduce the carbonyl group. In the case that the hydrogen on the carbon in the conjugated ring is replaced by different substituents, good reduction effect can be obtained. The catalyst has simple preparation mode and stable performance, and good chiral selection effect and conversion rate can still be obtained under the condition of high substrate / catalyst.

A process produces unsubstituted or at least monosubstituted α,ω-dicarboxylic acids or ketocarboxylic acids and unsubstituted or at least monosubstituted cycloalkanones by electrochemical oxidation of unsubstituted or at least monosubstituted, monounsaturated or poly unsaturated cycloalkenes and unsubstituted or at least monosubstituted, saturated cycloaliphatic hydrocarbons in the presence of an inorganic or organic nitrate salt in an electrolysis cell in a reaction medium in the presence of oxygen.

The utility model relates to the technical field of naphthenic oil, and discloses a naphthenic oil containing and pouring device which comprises a tank body, lifting rods are movably installed on the two sides of the top of the tank body, a connecting rod is fixedly installed on one side of the bottom of the tank body, a rotating plate is fixedly connected to the outer side of the connecting rod, and a gear motor is movably connected to the outer side of the rotating plate. Through the arrangement of the tank body, naphthenic oil can be conveniently contained, the lifting rods are installed on the two sides of the top of the tank body and movably connected with the side plates, so that the whole tank body can freely rotate around the lifting rods, when the naphthenic oil in the tank body needs to be poured out, a rotating plate can be driven to rotate through a gear motor, and a connecting rod is not installed in the center of the rotating plate, so that the naphthenic oil in the tank body can be conveniently poured out. And when the rotating plate rotates, the connecting rod can also drive the bottom of the tank body to incline, and the inclination angle can be adjusted according to rotation, so that oil pouring can be electrically driven, and manual operation is not needed.

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof.wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

A compound having formula I: R1 is hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic, aryl, heteroaryl, -NR7R8, -CO-R 10 or -NH-CO-R 10 L is a bond, a heterocyclic divalent group, a heteroaromatic divalent group, or an aromatic divalent group; M is a bond, an alkyl group, an aryl group, a heterocyclic divalent group, a heteroaromatic divalent group, or an aromatic divalent group; X is a bond, -O-, -S-, -SO2-, -CO-, -NR9-, -(CH2)m-, or a heterocyclic divalent group, where m is 1, 2, 3, 4, 5, or 6; Y is a bond, -NH-, a heterocyclic divalent group, a heteroaromatic divalent group, a divalent benzyl group, or an aromatic divalent group; and Z is hydrogen, halogen, alkyl, aryl, heterocyclic, heteroaromatic, -NR7R8, -CO-R 10 or -NH-CO-R 10 R7, R8, and R9 are independently hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic, or heteroaryl; and R 10 It can be -O-tert-butyl, -CH2CH2-phenyl, hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic or heteroaryl.

This invention discloses a method for constructing a macromolecular model of Hami oil-rich coal and its application. The molecular formula and functional group characteristics of the coal sample are determined through elemental analysis and infrared spectroscopy. A planar structural model is constructed using the Wiser model framework, and a stable configuration is obtained after geometric optimization. Finally, a pyrolysis reaction model containing multiple molecules is constructed through stacking. Targeting the high-oxygen and high-cycloalkane structural characteristics of Hami oil-rich coal, a C1... 128 H 82 NO 16 and C 111 H 88 NO 28 Two precise models were used, and the accuracy of the calculated infrared spectra was verified by comparing them with experimental spectra. ReaxFF molecular dynamics simulations were performed using this model, revealing the influence of different heating rates and pyrolysis temperatures on product distribution. The optimal simulation temperature and critical values ​​for pyrolysis rate control were determined, and the difference in ethylene formation pathways between alkyl-rich coal and ether-rich coal was analyzed. This invention fills the gap in precise models for Hami oil-rich coal, providing key theoretical basis and parameter guidance for optimizing pyrolysis processes, achieving targeted regulation, and improving energy efficiency.

The application provides a sealing material and a preparation method and application thereof, and the structural formula of the sealing material is: wherein n is greater than or equal to m, and m+n=1, R1 and R2 are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl. The sealing material provided by the application has high stability, good sealing effect, improved structural stability and safety performance of the battery, and prolonged cycle life of the battery.

The present invention discloses a small molecule active peptide and its preparation method and application, relating to the field of antimicrobial peptide technology. The small molecule active peptide of the present invention includes a compound shown in Formula I, or a stereoisomer, tautomer, nitrogen oxide, solvate, hydrate, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable ether or prodrug of the compound shown in Formula I: #imgabs0# wherein R1 and R2 are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylamino, haloalkyl or cycloalkyl, or R1 and R2 are linked to form a cycloalkyl. The small molecule active peptide of the present invention is obtained by modifying the TP4 polypeptide sequence. Compared with TP4, it has fewer amino acids, low synthesis cost, and relatively higher stability and safety. In addition, it has excellent antibacterial effect and anti-resistance ability.

The invention discloses a substituted benzo [d] oxazole compound as shown in a general formula (I) as well as a preparation method and application of the substituted benzo [d] oxazole compound. The compound has a benzo [d] oxazole-pyridine skeleton structure, in which: R is selected from C-Cbranched alkyl sulfinyl or C-Ccycloalkyl sulfinyl, preferably isopropyl sulfinyl; r is C-Calkyl; and R is C-Ccycloalkyl. According to the method, a platform preparation route is adopted, a sulfoxide center construction step is placed at the synthesis end, and the system temperature is maintained at 0-10 DEG C (preferably 1-3 hours) by accurately regulating and controlling the dosage (1.05-1.2 equivalents) of an oxidant and controlling the dropping speed, so that the generation (the content lt is 0.5%) of a sulfone byproduct is effectively inhibited, and the stereoselectivity control of the chiral center is realized. A biological activity test result shows that the compound has excellent insecticidal activity on agricultural pests such as brown planthopper, the LC value of the compound can be as low as 1.85 mg / L, the physicochemical property of the compound is suitable for preparation processing, and the compound can be widely applied to prevention and control of the agricultural pests.

In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of terpenoid cores. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising a terpenoid core or scaffold, such as 6 / 7 / 5 tricycloalkanes. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to tunably and scalably assemble common terpenoid cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The application discloses the use of a bifunctional chiral palladium catalyst that enables remote γ- and d-methylene C-H (hetero)arylation of cyclic carbocyclic acids. Specifically, the application discloses methods of enantioselective remote γ-C-H arylation or heteroarylation, δ-C-H arylation or heteroarylation, or sequential γ-methylene C-H arylation or heteroarylation of diverse free cycloalkane carboxylic acids comprising the use of palladium catalysts with chiral oxazoline-pyridone ligands.

The invention discloses mineral oil type transformer oil with low pour point and high gassing resistance and a preparation method thereof. The invention discloses mineral oil type transformer oil with low pour point and high gassing resistance. The mineral oil type transformer oil is prepared by blending the following components in percentage by mass: 10-40% of a first component and 60-90% of a second component, wherein the pour point of the first component is less than-25 DEG C, the kinematic viscosity at 40 DEG C is 8-11 mm < 2 > / s, the flash point is greater than 135 DEG C, the aromatic carbon rate is 2-5%, the naphthenic carbon rate is not less than 50%, and the gassing property is not higher than + 5 mm < 3 > / min; the pour point of the second component is not higher than-60 DEG C, the kinematic viscosity at 40 DEG C is 7-11 mm < 2 > / s, the flash point is greater than 135 DEG C, and the aromatic carbon rate is less than 1%. The pour point of the transformer oil is lower than-50 DEG C, and the gassing property is lower than + 10 mm < 3 > / min, so that the transformer oil can simultaneously meet the standard requirements of GB 2536-2011 and IEC60296: 2020, and can meet the use requirements of power equipment on low-temperature startability and long-term safe and stable operation in a special environment.

The present invention relates to a process for the preparation of unsubstituted or at least monosubstituted cycloalkanones by electrochemically oxidizing unsubstituted or at least monosubstituted saturated alicyclic hydrocarbons in the presence of inorganic or organic nitrates in an electrolytic cell in a reaction medium in the presence of oxygen.

Disclosed herein is a process for preparing a 1-(cycloalk-1-en-1-yl) acyl or 1-(cycloalkadien-1-yl) acyl derivative including isomerizing a conjugated intracyclic carbon-carbon double bond in the presence of a catalyst system including palladium (Pd) and molecular hydrogen or a hydrogen source.

The present invention relates to a chiral iridium hydride complex comprising a) a chiral (P, N)-ligand and b) a stabilized ketene ligand of formula (I), wherein R1 is selected from the group consisting of hydrogen, a C1-C500-alkyl group, a C2-C500-alkenyl group, a C1-C500-alkoxy group, a C2-C500-alkenyloxy group, a C1-C500-alkylamino group, a C2-C500-alkenyl amino group, a di-(C1-C500-alkyl) amino group, a di-(C2-C500-alkenyl) amino group, a N-(C1-C500-alkyl)-N-(C2-C500-alkenyl) amino group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyloxy group, a C3-C8-cycloalkylamino group, a N-(C1-C500-alkyl)-N-(C3-C8-cycloalkyl) amino group, and a pharmaceutically acceptable salt thereof; a C6-C14-aryl group, which may be substituted as further defined in the specification; r1a is selected from hydrogen, C1-C6-alkyl, C1-C6-alkylcarbonyl, or R1a and R1 together with the carbon atom to which R1a is attached and the carbonyl to which R1 is attached form a C5-C7-cycloalkanone ring wherein the C5-C7-cycloalkanone ring is unsubstituted or substituted by 1 to 4 substituents independently selected from C1-C6-alkyl and benzylidene, wherein the benzylidene group is unsubstituted or substituted by 1 to 5 substituents independently of one another selected from the group consisting of halogen, a C1-C500-alkyl group, a C1-C500-alkoxy group, a C1-C500-haloalkyl group, and a C1-C500-haloalkoxy group; r2 is selected from hydrogen, a C1-C500-alkyl group, a C1-C500-alkoxy group, a C1-C500-alkylamino group, a di-(C1-C500-alkyl) amino group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyloxy group, a C3-C8-cycloalkylamino group, an N-(C1-C500-alkyl)-N-(C3-C8-cycloalkyl) amino group, a C6-C14-aryl group, which may be substituted as further defined in the specification; and arrow represents a bond attached to an iridium atom; the present invention relates to chiral iridium hydride complexes, and to a method for producing optically active 4-substituted 1, 2, 3, 4-tetrahydroquinolines by enantioselective hydrogenation of the corresponding 4-substituted 1, 2-dihydroquinolines in the presence of such chiral iridium hydride complexes.

The present invention discloses a 7-hydroxyflavonoid compound, or an intermediate, prodrug, deuterated compound, pharmaceutically acceptable salt thereof. The structure of the 7-hydroxyflavonoid compound is shown as formula (I); in the formula: R1 is H or C1-C5 alkyl; R2 is H or OH; R3 is halogen; R4 is -X-linker-R'; X is N, O, S or absent, linker is an alkyl chain containing or not containing N, O, S atoms with a length of 0-6 atoms, and R' is alkyl, cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, C1-C6 cycloalkylamino or C1-C6 heterocycloalkylamino. The present invention also discloses a preparation method of the 7-hydroxyflavonoid compound, and the use of the 7-hydroxyflavonoid compound or an intermediate, prodrug, deuterated compound, pharmaceutically acceptable salt thereof. The present invention discloses that the 7-hydroxyflavonoid compound has good inhibitory activity against 3βHSD1. #imgabs0#

The present invention relates to cycloalkyl and heterocycloalkyl inhibitors, their preparation methods and applications. Specifically, the compounds of the present invention have the structure shown in formula (I), and the present invention also discloses a method for preparing the compounds and their use as KRAS inhibitors. G12C Use of inhibitors against KRAS G12C It has good selective inhibitory effect and has better pharmacodynamics, pharmacokinetic properties and lower toxic side effects.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

The present application relates to a beta-lactamase inhibitor intermediate co-crystal or salt, a preparation method and application thereof, and belongs to the technical field of pharmaceutical chemical engineering. The structural formula is as follows: R2 represents benzyl or allyl; R3 represents an alkylamine group with a protective group, a cycloalkylamine group, an aromatic amine group, and a derivative amine group. The preparation method comprises the following steps: dissolving compound I in a solvent A, adding a base solution to react under the condition of less than 0℃, then adding an acid to adjust the pH to be acidic, adding a solvent B to extract the product, separating the layers, and leaving the organic phase; and then adding a beta-lactamase inhibitor side chain R3H to react. The beta-lactamase inhibitor is prepared by using the intermediate co-crystal or the new salt, the purity is greater than 99.90%, the pharmaceutical quality standard of the crude drug is met, the process operation is safe, simple, convenient, green and environment-friendly; the atom economy, the selectivity, the purity and the yield of each step reaction are high, and the production can be enlarged.

The invention belongs to the field of chemical synthesis, and particularly relates to a hydroxylamine compound containing an aryl allyl structure as well as a synthesis method and application of the hydroxylamine compound. The structure of the hydroxylamine compound is shown as a formula (I), and in the formula (I), R1 is selected from unsubstituted alkyl, cycloalkyl, naphthyl, heteroaryl or substituted or unsubstituted phenyl; r2 is selected from substituted or unsubstituted phenyl; the synthesis method comprises the following steps: by taking nitrone and boric acid as raw materials, efficiently synthesizing through a boron migration reaction under the catalysis of R-1, 1 '-co-2-naphthol. The synthesis method has the characteristics that a metal catalyst is not needed, the operation is simple and convenient, the organic boric acid is easy to obtain and environment-friendly, the reaction condition is mild, the substrate application range is wide, the yield is medium to good and the like, and a new thought is provided for synthesis of the hydroxylamine compound. In-vitro experiments show that the compound has remarkable proliferation inhibition activity on A549, HeLa and MV-411 tumor cells, and has the development potential of antitumor drugs.

This invention provides compounds of general formula (I) or pharmaceutically acceptable salts, precursors, solvates thereof, and their use in the preparation of diagnostic drugs for diabetic nephropathy, wherein (I) X is selected from carbon or nitrogen; R 1 Selected from hydrogen or alkyl; R 2 It is one or more substituents on the benzene ring or pyridine ring, R 2 Independently selected from one or more of hydrogen, halogen, hydroxyl, cyano, nitro, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C6 cycloalkoxy, C1-C6 alkylamino, C3-C6 cycloalkylamino, halo-C1-C6 alkyl, halo-C3-C6 cycloalkyl, halo-C1-C6 alkoxy, halo-C3-C6 cycloalkoxy, halo-C1-C6 alkylamino, halo-C3-C6 cycloalkylamino, C6-C8 aryl or C5-C8 heteroaryl, and R 2 At least one atom of these substituents, or the entire substituent, is replaced by a radioactive nuclide. The diagnostic drugs and methods for diabetic nephropathy of the present invention are non-invasive diagnostic techniques, with advantages such as less discomfort for the subjects and fewer contraindications.

It is an object of the present invention to identify a novel analog of carbacyclic phosphatidic acid that is a cyclic phosphatidic acid derivative, and to clarify the physiological activity thereof. According to the present invention, a compound represented by the following formula (1) is provided:wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, and these groups may optionally comprise a cycloalkane ring or an aromatic ring; and M represents a hydrogen atom or a counter cation.

The present invention relates to a process for the preparation of an oxa-bicycloalkene from a hydroxyalkyl cycloalkanone in the presence of an acid and using a thin film evaporator and the use of a thin film evaporator to conduct such a process.